BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 12218888)

  • 1. [Immune-based therapies and HIV infection].
    Weiss L
    Ann Med Interne (Paris); 2002 Jun; 153(4):227-36. PubMed ID: 12218888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies.
    Angel JB
    AIDS Read; 2001 Apr; 11(4):209-21. PubMed ID: 11392678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients.
    Mitsuyasu R
    J Infect Dis; 2002 May; 185 Suppl 2():S115-22. PubMed ID: 12001032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
    Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP;
    AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
    López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
    Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune based therapy update.
    Proj Inf Perspect; 1998 Sep; (25):17-9. PubMed ID: 11365845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy of HIV infection].
    Harrer T
    Wien Med Wochenschr; 1998; 148(23-24):560-6. PubMed ID: 10189687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.
    Chong SY; Egan MA; Kutzler MA; Megati S; Masood A; Roopchard V; Garcia-Hand D; Montefiori DC; Quiroz J; Rosati M; Schadeck EB; Boyer JD; Pavlakis GN; Weiner DB; Sidhu M; Eldridge JH; Israel ZR
    Vaccine; 2007 Jun; 25(26):4967-82. PubMed ID: 17335943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy and therapeutic vaccines in HIV infection.
    García F; Ruiz L; López-Bernaldo de Quirós JC; Moreno S; Domingo P
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():84-104. PubMed ID: 16373008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
    Aiuti F; Mezzaroma I
    AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s.
    Valdez H; Mitsuyasu R; Landay A; Sevin AD; Chan ES; Spritzler J; Kalams SA; Pollard RB; Fahey J; Fox L; Namkung A; Estep S; Moss R; Sahner D; Lederman MM
    J Infect Dis; 2003 Jan; 187(2):320-5. PubMed ID: 12552459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal data.
    Mogg R; Mehrotra DV
    Stat Med; 2007 Feb; 26(3):484-97. PubMed ID: 16625520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A primer on HIV type 1-specific immune function and REMUNE.
    Moss RB; Giermakowska WK; Savary JR; Theofan G; Daigle AE; Richieri SP; Jensen FC; Carlo DJ
    AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S167-75. PubMed ID: 9672235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of antiretroviral therapy during chronic SIV infection leads to rapid reduction in viral loads and the level of T-cell immune response.
    Boyer JD; Kumar S; Robinson T; Parkinson R; Wu L; Lewis M; Weiner DB
    J Med Primatol; 2006 Aug; 35(4-5):202-9. PubMed ID: 16872283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results.
    Andrieu JM; Lu W
    J Intern Med; 2007 Feb; 261(2):123-31. PubMed ID: 17241177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?
    Marchetti G; Franzetti F; Gori A
    J Antimicrob Chemother; 2005 Apr; 55(4):401-9. PubMed ID: 15731201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Honing the immune attack on HIV.
    Gilden D
    GMHC Treat Issues; 1996 Dec; 10(12):8-11. PubMed ID: 11364019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.